| Oct 8 |
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
|
| Oct 8 |
AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint
|
| Oct 8 |
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
|
| Oct 7 |
AstraZeneca reports positive results for Airsupra v. albuterol study
|
| Oct 7 |
5 Large Drug Stocks to Watch From a Thriving Industry
|
| Oct 7 |
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
|
| Oct 7 |
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
|
| Oct 7 |
AstraZeneca looks to boost cardiovascular pipeline with $2B license deal
|
| Oct 7 |
AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history
|
| Oct 4 |
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
|
